Sujuan Yang
Research Subjects
Research Interests
Sujuan Yang has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Anirban Maitra
Laura and Isaac Perlmutter Cancer Center, New York University Grossman School of Medicine, NYU Langone Health, New York City, New York, USA
1 shared publication - Cassian Yee
Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
1 shared publication - Chia-Chin Wu
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
1 shared publication Elena V. Rodriges Blanko
Department of Cancer Biology, Metastasis Research Center
1 shared publication- Elizabeth J. Shpall
MD Anderson Cancer Center
1 shared publication - Hikaru Sugimoto
Department of Cancer Biology, Metastasis Research Center, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 19 April 2018
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 3 (8)
Generation and testing of clinical-grade exosomes for pancreatic cancer
Exosomes are extracellular vesicles produced by all cells with a remarkable ability to efficiently transfer genetic material, including exogenously loaded siRNA, to cancer cells. Here, we report on a bioreactor-based, large-scale production of clinical-grade exosomes employing good manufacturing practice (GMP) standards. A standard operating procedure was established to generate engineered exosomes with the ability to target oncogenic Kras (iExosomes). The clinical-grade GMP iExosomes were tested in multiple in vitro and in vivo studies to confirm suppression of oncogenic Kras and an increase in the survival of several mouse models with pancreatic cancer. We perform studies to determine the shelf life, biodistribution, toxicology profile, and efficacy in combination with chemotherapy to inform future clinical testing of GMP iExosomes. Collectively, this report illustrates the process and feasibility of generating clinical-grade exosomes for various therapies of human diseases.
- 19 April 2018
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 3 (8)
Top Cited PapersOpen AccessGeneration and testing of clinical-grade exosomes for pancreatic cancer
Exosomes are extracellular vesicles produced by all cells with a remarkable ability to efficiently transfer genetic material, including exogenously loaded siRNA, to cancer cells. Here, we report on a bioreactor-based, large-scale production of clinical-grade exosomes employing good manufacturing practice (GMP) standards. A standard operating procedure was established to generate engineered exosomes with the ability to target oncogenic Kras (iExosomes). The clinical-grade GMP iExosomes were tested in multiple in vitro and in vivo studies to confirm suppression of oncogenic Kras and an increase in the survival of several mouse models with pancreatic cancer. We perform studies to determine the shelf life, biodistribution, toxicology profile, and efficacy in combination with chemotherapy to inform future clinical testing of GMP iExosomes. Collectively, this report illustrates the process and feasibility of generating clinical-grade exosomes for various therapies of human diseases.